Showing 1841-1850 of 2314 results for "".
- Oculus Debuts Dual Testing Functionality on Easyfield VR for Enhanced Visual Field Assessmenthttps://modernod.com/news/oculus-debuts-dual-testing-functionality-on-easyfield-vr-for-enhanced-visual-field-assessment/2482416/Oculus has announced the debut of dual testing functionality on its Oculus Easyfield VR, which allows for both Frequency Doubling Perimetry (FDP) and Standard Automated Perimetry (SAP). The integration of Frequency Doubling Perimetry into the Easyfield VR allows for the potent
- Aldeyra Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalaphttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-dry-eye-disease-clinical-trial-of-reproxalap/2482391/Aldeyra Therapeutics announced the primary endpoint has been achieved in its phase 3 trial of investigational reproxalap for dry eye disease. In the randomized, double-masked, vehicle-controlled dry eye chamber clinical trial, reproxalap 0.25% was statistic
- Annexon Provides Update on ARCHER II Global Registrational Program in GAhttps://modernod.com/news/annexon-provides-update-on-archer-ii-global-registrational-program-in-geographic-atrophy/2482386/Annexon announced patient dosing was initiated in the global pivotal phase 3 ARCHER II trial evaluating ANX007 for the treatment of geographic atrophy (GA). The company says the trial is the only GA pivotal program utilizing visual protection as the global regulatory-aligned primary end
- Enrollment Begins for Ocular Therapeutix’s Axpaxli Phase 3 SOL-R Wet AMD Studyhttps://modernod.com/news/ocular-therapeutixs-axpaxli-phase-3-sol-r-wet-amd-study-begins-enrollment/2482382/Ocular Therapeutix announced that the first patients have been enrolled in the phase 3 SOL-R clinical trial evaluating repeat dosing of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of patients with wet age-related macular degeneration (wet AMD). Accor
- Topcon and Orbis International Partner to Expand Diabetic Retinopathy Screening in Rwandahttps://modernod.com/news/topcon-and-orbis-international-partner-to-expand-diabetic-retinopathy-screening-in-rwanda/2482367/Topcon Healthcare has patnered with Orbis International and the Rwanda International Institute of Ophthalmology (RIIO) to expand diabetic retinopathy screening in Rwanda. Topcon has donated NW400 and NW500 robotic retinal cameras for use in much-needed diab
- OcuCell Announces Funding from AltruVision and New Board Appointmentshttps://modernod.com/news/ocucell-announces-funding-from-altruvision-and-leadership-changes/2482354/OcuCell announced it has received funding from AltruVision to enable OcuCell to continue advancing its Endo-Tek and Epi-Tek ocular cell therapy treatments. Financial terms of the funding were not disclosed. Established in 1957, AltruVision recovers over 1,500 eye don
- PharmAbcine Advances Phase 1 Clinical Trial of PMC-403 for nAMDhttps://modernod.com/news/pharmabcine-advances-phase-1-clinical-trial-of-pmc-403-for-namd/2482343/PharmAbcine, Inc., a South Korea-based clinical-stage developer of medical therapeutics, announced the Safety Review Committee (SRC) approval of single 3-mg dose for the third cohort in phase 1 clinical trial of PMC-403, the company&rsquo
- FDA Approves Genentech’s Vabysmo Prefilled Syringe for AMD, DME, and RVOhttps://modernod.com/news/genentechs-vabysmo-prefilled-syringe-approved-by-fda-for-amd-dme-and-rvo/2482342/Genentech announced FDA approval of Vabysmo (faricimab-svoa) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema after retinal vein occlusion (RVO). The company advised that Vabysmo
- J&J's Nipocalimab Significantly Improves Sjögren’s Disease Activity in a Phase 2 Studyhttps://modernod.com/news/jjs-nipocalimab-significantly-improves-sjogrens-disease-activity-in-a-phase-2-study/2482323/Johnson & Johnson announced that patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline (primary endpoint) in the phase 2 DAHLIAS dose-rang
- 2024 Kavli Prize in Neuroscience Awarded for the Discovery of 'Face Areas' in the Brainhttps://modernod.com/news/2024-kavli-prize-in-neuroscience-awarded-for-the-discovery-of-face-areas-in-the-brain/2482322/The 2024 Kavli Prize in Neuroscience honors Nancy Kanwisher, PhD, (Massachusetts Institute of Technology); Doris Ying Tsao, PhD (University of California, Berkeley); and Winrich Freiwald, Ph.D. (Rockefeller University) for the discovery of a specialized system within the brain to r